Abbott broadens access to cutting-edge biosimilars in key emerging markets

Abbott to commercialize several biosimilar molecules in key emerging markets in latin america, southeast asia, the middle east and africa spain-based global biotech leader mabxience holdings s.l. to develop, manufacture and supply the biosimilar molecules first molecules expected to launch as early as 2025, offering new treatment options that leverage the latest in scientific breakthroughs for people in emerging markets abbott park, ill.
ABT Ratings Summary
ABT Quant Ranking